Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Clinical trial NCT02229396 · COMPLETED
Trial details
- NCT number
- NCT02229396
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-04
- Primary completion
- 2016-04-26
- Enrollment
- 695
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.